Research Analysts Issue Forecasts for Lifecore Biomedical, Inc.’s Q1 2026 Earnings (NASDAQ:LFCR)

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Equities research analysts at Barrington Research issued their Q1 2026 EPS estimates for shares of Lifecore Biomedical in a note issued to investors on Monday, October 7th. Barrington Research analyst M. Petusky forecasts that the company will post earnings of ($0.28) per share for the quarter. Barrington Research currently has a “Market Perform” rating on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.89) per share. Barrington Research also issued estimates for Lifecore Biomedical’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.60) EPS and FY2027 earnings at ($0.38) EPS.

Separately, Craig Hallum assumed coverage on Lifecore Biomedical in a research note on Thursday, September 5th. They set a “buy” rating and a $8.00 target price for the company.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $5.09 on Tuesday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 1.06 and a current ratio of 2.08. Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $8.90. The stock has a market capitalization of $154.34 million, a P/E ratio of -1.52 and a beta of 0.95. The stock has a fifty day moving average of $5.16 and a 200-day moving average of $5.52.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $37.89 million for the quarter. Lifecore Biomedical had a net margin of 9.37% and a negative return on equity of 515.12%.

Insider Activity at Lifecore Biomedical

In related news, major shareholder Wynnefield Partners Small Cap bought 122,930 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were purchased at an average price of $4.10 per share, with a total value of $504,013.00. Following the completion of the purchase, the insider now owns 2,095,783 shares in the company, valued at $8,592,710.30. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 14.61% of the stock is owned by insiders.

Institutional Trading of Lifecore Biomedical

Hedge funds have recently made changes to their positions in the company. Allegheny Financial Group LTD bought a new position in Lifecore Biomedical in the 2nd quarter valued at approximately $52,000. Renaissance Technologies LLC acquired a new position in shares of Lifecore Biomedical during the second quarter worth $56,000. SG Americas Securities LLC bought a new stake in shares of Lifecore Biomedical in the first quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Lifecore Biomedical in the first quarter worth $58,000. Finally, Boston Partners bought a new position in Lifecore Biomedical during the 1st quarter worth $104,000. 83.36% of the stock is owned by institutional investors and hedge funds.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.